ReviewThe Journal of clinical investigation2007
Lymphocytes, neuropeptides, and genes involved in alopecia areata.
Review in The Journal of clinical investigation, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 95 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Cryotherapy Versus Intralesional Corticosteroid Injection In Treatment Of Alopecia Areata: Trichoscopic Evaluation
Efficacy of Combined Microneedling With Methotrexate in Treatment of Alopecia Areata
Who cites it
95 citing papers in PubMed, 306 citations in OpenAlex.
- Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Trial
- Long-term safety and efficacy of ritlecitinib in adults and adolescents with alopecia areata and at least 25% scalp hair loss: Results from the ALLEGRO-LT phase 3, open-label study.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025Trial
- Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial.Archives of dermatological research · 2024Trial
- Patient-Reported Satisfaction with Hair Regrowth in a Study of Ritlecitinib in Alopecia Areata: Results from ALLEGRO-2b/3.Dermatology (Basel, Switzerland) · 2024Trial
- The prevalence of systemic sclerosis is increased among patients with alopecia areata: a population-based study.Immunologic research · 2019Trial
- Trial
- The Possible Role of Antibodies in Alopecia: A Narrative Review.Antibodies (Basel, Switzerland) · 2026Review
- JAK Inhibitors for Alopecia Areata: Approved Therapies, Efficacy, and Unanswered Questions.Drug design, development and therapy · 2026Review
- Rationale and Design of a Novel, Phase 3, External and Synthetic Placebo-Controlled Clinical Trial of Ritlecitinib 50 mg and 100 mg for Alopecia Areata.Dermatology and therapy · 2025Article
- Ophthalmologic Comorbidities in Alopecia Areata.Journal of clinical medicine · 2025Review
- TScience advances · 2025Article
- Efficacy and Safety of Long-Term Azathioprine Therapy for Severe Alopecia Areata: A 10-Year Cohort Study.Journal of cosmetic dermatology · 2025Article
- The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland.Journal of patient experience · 2025Article
- Distribution characteristics of immune infiltration and lymphovascular invasion in patients with breast cancer skin recurrence.Cancer immunology, immunotherapy : CII · 2024Article
- Pathogenesis of Alopecia Areata and Vitiligo: Commonalities and Differences.International journal of molecular sciences · 2024Review
- Good efficacy achieved by telitacicept in treatment of systemic lupus erythematosus with alopecia areata.Archives of medical science : AMS · 2024Article
- Pathogenesis and regenerative therapy in vitiligo and alopecia areata: focus on hair follicle.Frontiers in medicine · 2024Review
- The prognostic significance of skin involvement in breast cancer patients with chest wall recurrence.Annals of medicine · 2023Article
- Alopecia Areata: Current Treatments and New Directions.American journal of clinical dermatology · 2023Review
- Hair Loss Profiles and Ritlecitinib Efficacy in Patients with Alopecia Areata: Post Hoc Analysis of the ALLEGRO Phase 2b/3 Study.Dermatology and therapy · 2023Article
35 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many lessons in autoimmunity - particularly relating to the role of immune privilege and the interplay between genetics and neuroimmunology - can be learned from the study of alopecia areata, the most common cause of inflammation-induced hair loss. Alopecia areata is now understood to represent an organ-restricted, T cell-mediated autoimmune disease of hair follicles. Disease induction is associated with collapse of hair follicle immune privilege in both humans and in animal models. Here, the role of HLA associations, other immunogenetic factors, and neuroendocrine parameters in alopecia areata pathogenesis are reviewed. This instructive and clinically significant model disease deserves more widespread interest in the immunology community.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.